Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sirolimus for focal cortical dysplasia type II–safety and seizure control
jRCTs011180016Completed
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of sirolimus in Focal Cortical Dysplasia Type 2 (FCD2). Primary endpoint: Safety in clinical research enforcement and presence or absence of occurrence of adverse events. Started Feb 2018; status: completed.
02
Drugs
sirolimus
03
Conditions
Focal Cortical Dysplasia Type 2 (FCD2)
Beyond the preview
Go deeper on jRCTs011180016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs011180016.